Precision Medicine: The Future of ARPI-PARP Combos and PSMA PET Imaging

5 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
At the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium, a roundtable of expert panelists convened to discuss the latest research and practice updates related to metastatic hormone-sensitive prostate cancer (mHSPC). Dr. Tanya Dorff of City of Hope Comprehensive Cancer Center was joined by Drs. Dan Childs, Andrew Hahn, Cora Sternberg, and Vadim Koshkin in the discussion.

In the fourth part of the roundtable, the panel zooms in on the evolving use of radium, enzalutamide, and other therapeutic agents in prostate cancer, touching on patient preference trials, clinical experiences in different regions, and the impact of combination therapies, including AR pathway inhibitors, PARP inhibitors, and PSMA-targeted treatments, while also debating the utility of PSMA PET scans for disease monitoring and the need for precision medicine in treatment selection.
Category
Oncology
Be the first to comment

Up Next